| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Reproductive Endocrine Unit, Department of Medicine, National Center for Infertility Research, Pediatric Surgical Research Laboratory, Massachusetts General Hospital, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Nelly Pitteloud, M.D., Reproductive Endocrine Unit and National Center for Infertility Research, Bartlett Hall Extension 5, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: npitteloud{at}partners.org
As our knowledge of the molecular mechanisms underlying idiopathic hypogonadotropic hypogonadism (IHH) expands, it becomes increasingly important to define the phenotypic spectrum of IHH. In this study we examined historical, clinical, biochemical, histological, and genetic features in 78 men with IHH to gain further insight into the phenotypic heterogeneity of the syndrome. We hypothesized that at least some of the spectrum of phenotypes could be explained by placing the disorder into a developmental and genetic context.
Thirty-eight percent of the population had Kallmann syndrome (KS; IHH with anosmia), 54% had normosmic IHH, and 8% had acquired IHH after completion of puberty. Phenotypically, KS represented the most severe subtype (87% with complete absence of any history or signs of spontaneous pubertal development), normosmic IHH displayed the most heterogeneity (41% with some evidence of spontaneous puberty), and acquired IHH after completion of puberty clustered at the mildest end (all had complete puberty).
Classification based on historical or clinical evidence of prior pubertal development, rather than the presence or absence of sense of smell, served to distinguish the population more clearly with respect to other clinical and biochemical features. Comparing IHH patients according to the absence (68%) or presence (24%) of some prior pubertal development revealed significant differences in testicular size (3.3 ± 0.2 vs. 11.8 ± 1.2 ml; P < 0.001), incidence of cryptorchidism (40% vs. 5%; P < 0.05), microphallus (21% vs. 0%; P < 0.05), inhibin B levels (45 ± 4 vs. 144 ± 20 pg/ml; P < 0.0001), and Mullerian inhibitory substance levels (9.8 ± 1.4 vs. 2 ± 0.5 ng/ml). Most familial cases had no pubertal development (95% vs. 5%; P < 0.001); males with mutations in the KAL gene displayed the most severe phenotype.
Mean gonadotropins levels (LH, 1.8 ± 0.1 vs. 2.9 ± 0.4 IU/liter; FSH, 2.2 ± 0.2 vs. 3.3 ± 0.3 IU/liter; P < 0.05) and the finding of apulsatile LH secretion based on frequent sampling (80% vs. 55%; P < 0.05) were statistically different between patients lacking and those exhibiting partial pubertal development, but the overlap was extensive.
The use of clinical parameters (presence or absence of some evidence of prior pubertal development, cryptorchidism, and microphallus), biochemical markers of testicular growth and differentiation (inhibin B and Mullerian inhibitory substance), and genetic evidence provides insight into the time of onset and the severity of GnRH deficiency. Viewing IHH in the full context of its developmental, genetic, and biochemical complexity permits greatest insight into its phenotypic variability.
This work was supported by Grants R01-HD-15788, and M01-RR-01066 and by the NICHHD/NIH through Cooperative Agreements U54-HD-28138 and U54-DK-07028-24 as part of the Specialized Cooperative Centers Program in Reproduction Research.
Abbreviations: AHH, Acquired idiopathic hypogonadotropic hypogonadism after completion of puberty; BMI, body mass index; CV, coefficient of variation; HPG, hypothalamic-pituitary-gonadal; IB, inhibin B; IHH, idiopathic hypogonadotropic hypogonadism; 2nd IRP, Second International Reference Preparation; KS, Kallmann syndrome; MIS, Mullerian inhibitory substance; nIHH, normosmic idiopathic hypogonadotropic hypogonadism; TV, testicular volume; X-KS, X-linked form of Kallmann syndrome.
This article has been cited by other articles:
![]() |
P. A. Boepple, F. J. Hayes, A. A. Dwyer, T. Raivio, H. Lee, W. F. Crowley Jr, and N. Pitteloud Relative Roles of Inhibin B and Sex Steroids in the Negative Feedback Regulation of Follicle-Stimulating Hormone in Men across the Full Spectrum of Seminiferous Epithelium Function J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1809 - 1814. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Cotton, M. K. O'Bryan, and B. T. Hinton Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction Endocr. Rev., April 1, 2008; 29(2): 193 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salenave, P. Chanson, H. Bry, M. Pugeat, S. Cabrol, J. C. Carel, A. Murat, P. Lecomte, S. Brailly, J.-P. Hardelin, et al. Kallmann's Syndrome: A Comparison of the Reproductive Phenotypes in Men Carrying KAL1 and FGFR1/KAL2 Mutations J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 758 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Raivio, J. Falardeau, A. Dwyer, R. Quinton, F. J. Hayes, V. A. Hughes, L. W. Cole, S. H. Pearce, H. Lee, P. Boepple, et al. Reversal of Idiopathic Hypogonadotropic Hypogonadism N. Engl. J. Med., August 30, 2007; 357(9): 863 - 873. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Raivio, A. M Wikstrom, and L. Dunkel Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome Eur. J. Endocrinol., January 1, 2007; 156(1): 105 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cerrato, J. Shagoury, M. Kralickova, A. Dwyer, J. Falardeau, M. Ozata, G. Van Vliet, P. Bouloux, J. E Hall, F. J Hayes, et al. Coding sequence analysis of GNRHR and GPR54 in patients with congenital and adult-onset forms of hypogonadotropic hypogonadism Eur. J. Endocrinol., November 1, 2006; 155(suppl_1): S3 - S10. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Antelli, L. Baldazzi, A. Balsamo, P. Pirazzoli, A. Nicoletti, M. Gennari, and A. Cicognani Two novel GnRHR gene mutations in two siblings with hypogonadotropic hypogonadism. Eur. J. Endocrinol., August 1, 2006; 155(2): 201 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pitteloud, J. S. Acierno Jr., A. Meysing, A. V. Eliseenkova, J. Ma, O. A. Ibrahimi, D. L. Metzger, F. J. Hayes, A. A. Dwyer, V. A. Hughes, et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism PNAS, April 18, 2006; 103(16): 6281 - 6286. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pitteloud, J. S. Acierno Jr., A. U. Meysing, A. A. Dwyer, F. J. Hayes, and W. F. Crowley Jr. Reversible Kallmann Syndrome, Delayed Puberty, and Isolated Anosmia Occurring in a Single Family with a Mutation in the Fibroblast Growth Factor Receptor 1 Gene J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1317 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Young, P. Chanson, S. Salenave, M. Noel, S. Brailly, M. O'Flaherty, G. Schaison, and R. Rey Testicular Anti-Mullerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 724 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xia, Y. Sidis, and A. Schneyer Overexpression of Follistatin-Like 3 in Gonads Causes Defects in Gonadal Development and Function in Transgenic Mice Mol. Endocrinol., April 1, 2004; 18(4): 979 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pitteloud, J. Villegas, A. A. Dwyer, W. F. Crowley Jr., M. J. McPhaul, and F. J. Hayes Acute Stress Masking the Biochemical Phenotype of Partial Androgen Insensitivity Syndrome in a Patient with a Novel Mutation in the Androgen Receptor J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1053 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ivell and S. Hartung The molecular basis of cryptorchidism Mol. Hum. Reprod., April 1, 2003; 9(4): 175 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pitteloud, F. J. Hayes, A. Dwyer, P. A. Boepple, H. Lee, and W. F. Crowley Jr. Predictors of Outcome of Long-Term GnRH Therapy in Men with Idiopathic Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4128 - 4136. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |